Gastrointestinal safety of triflusal solution in healthy volunteers: a proof of concept endoscopic study

[1]  Alan S. Brown,et al.  ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. , 2011, Circulation.

[2]  J. García-Rafanell,et al.  Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjectsA single, randomized, two-way cross-over, open-label phase I study , 2010, Arzneimittelforschung.

[3]  P Michael Ho,et al.  Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. , 2009, JAMA.

[4]  J. Hirsh,et al.  Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[5]  J. Hirsh,et al.  Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[6]  J. Fraj,et al.  Safety of triflusal (antiplatelet drug) in patients with aspirin‐exacerbated respiratory diseases , 2007, Allergy.

[7]  B. Horne,et al.  Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.

[8]  J. Ornato,et al.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie , 2007, Journal of the American College of Cardiology.

[9]  S. Jacob,et al.  Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? , 2007, Interactive cardiovascular and thoracic surgery.

[10]  Adnan I. Qureshi,et al.  Guidelines for the Early Management of Adults With Ischemic Stroke , 2007 .

[11]  M. Gilard,et al.  Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin , 2006, Journal of thrombosis and haemostasis : JTH.

[12]  U. Moretti,et al.  Upper gastrointestinal bleeding associated with antiplatelet drugs , 2006, Alimentary pharmacology & therapeutics.

[13]  J. Ferro,et al.  Triflusal for Preventing Serious Vascular Events in People at High Risk , 2005, The Cochrane database of systematic reviews.

[14]  C. Mestres,et al.  Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[15]  A. Salvador,et al.  Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. , 2004, Journal of the American College of Cardiology.

[16]  F. Pérez-Gómez,et al.  Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation , 2004 .

[17]  A. Culebras,et al.  Triflusal vs aspirin for prevention of cerebral infarction , 2004, Neurology.

[18]  J. Ferro,et al.  Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction: The TACIP Study: A Randomized, Double-Blind, Multicenter Trial , 2003, Stroke.

[19]  A. Morelli,et al.  Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. , 2003, Gastroenterology.

[20]  Á. Lanas,et al.  Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs , 2003, European journal of gastroenterology & hepatology.

[21]  Carl J Pepine,et al.  ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.

[22]  P. Pouderoux,et al.  [Deglutition disorders in the elderly. Management]. , 2001, Presse medicale.

[23]  D. Strubel,et al.  Les troubles de la déglutition du sujet âgé : Aspects épidémiologiques. , 2001 .

[24]  J. M. Cruz-Fernández.  Antiplatelet drugs in the treatment of acute coronary syndromes: Focus on cyclooxygenase inhibitors , 2001 .

[25]  A. Castro‐Beiras,et al.  Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. , 2000, European heart journal.

[26]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[27]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[28]  C. Hawkey,et al.  Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. , 1991, British journal of clinical pharmacology.

[29]  M. Masotti,et al.  Five years of angiographic and clinical follow-up after successful percutaneous transluminal coronary angioplasty. , 1989, European heart journal.

[30]  M. Masotti,et al.  Prevention of aortocoronary vein-graft attrition with low-dose aspirin and triflusal, both associated with dipyridamole: a randomized, double-blind, placebo-controlled trial. , 1989, European heart journal.

[31]  J. García-Rafanell,et al.  Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets. , 1986, Archives internationales de pharmacodynamie et de therapie.

[32]  M. Vincent,et al.  Improvement of global and regional left ventricular function in patients with previous myocardial infarction by a new beta 1 adrenoceptor partial agonist, ICI 118,587. , 1982, European heart journal.

[33]  J. Hoftiezer,et al.  COMPARISON OF THE EFFECTS OF REGULAR AND ENTERIC-COATED ASPIRIN ON GASTRODUODENAL MUCOSA OF MAN , 1980, The Lancet.

[34]  R. Nelson,et al.  Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. , 1980, The New England journal of medicine.

[35]  G. Ladurner,et al.  IMPROVED LOCALISATION BY SUBTRACTION OF E.M.I. SCANS , 1975, The Lancet.

[36]  V. Riambau-Alonso,et al.  Estudio epidemiológico observacional para evaluar el manejo de los trastornos gastrointestinales en el paciente con tratamiento antiagregante , 2009 .

[37]  Sanjay Kaul,et al.  ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. , 2008, Journal of the American College of Cardiology.

[38]  D. Murdoch,et al.  Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation. , 2006, Drugs.

[39]  P. Denis,et al.  Les troubles de la déglutition du sujet âgé , 2002 .

[40]  Role of causality assessment in pharmacovigilance , 1997 .

[41]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[42]  A. Auteri,et al.  Triflusal in the treatment of patients with chronic peripheral arteriopathy: multicentre double-blind clinical study vs placebo. , 1995, International journal of clinical pharmacology research.

[43]  E. Alegrı́a,et al.  Protective effect of triflusal against acute myocardial infarction in patients with unstable angina: results of a Spanish multicenter trial. Grupo de Estudio del Triflusal en la Angina Inestable. , 1993, Cardiology.